Cargando…

Association Among Lipid Accumulation Product, Chinese Visceral Obesity Index and Diabetic Retinopathy in Patients with Type 2 Diabetes: A Cross-Sectional Study

BACKGROUND AND AIM: Obesity often coexists with diabetes, especially abdominal obesity, recognized as a risk factor for diabetic complications. Diabetic retinopathy (DR), as one of the most common microvascular complications of diabetes, may be associated with these indices. Lipid accumulation produ...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xin, Li, Hui-Yao, Yu, Zi-Wei, Zhang, Yi-Tong, Tong, Xue-Wei, Gao, Xin-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721021/
https://www.ncbi.nlm.nih.gov/pubmed/35002269
http://dx.doi.org/10.2147/DMSO.S348195
_version_ 1784625249421099008
author Li, Xin
Li, Hui-Yao
Yu, Zi-Wei
Zhang, Yi-Tong
Tong, Xue-Wei
Gao, Xin-Yuan
author_facet Li, Xin
Li, Hui-Yao
Yu, Zi-Wei
Zhang, Yi-Tong
Tong, Xue-Wei
Gao, Xin-Yuan
author_sort Li, Xin
collection PubMed
description BACKGROUND AND AIM: Obesity often coexists with diabetes, especially abdominal obesity, recognized as a risk factor for diabetic complications. Diabetic retinopathy (DR), as one of the most common microvascular complications of diabetes, may be associated with these indices. Lipid accumulation product (LAP) and Chinese visceral obesity index (CVAI) are novel visceral obesity indicators, which have been proven to be an influential factor predicting type 2 diabetes (T2DM). However, the correlation among LAP, CVAI, and DR still lacks systematic research in T2DM. The study aimed to explore the relationship among LAP, CVAI levels in different DR stages of T2DM patients and the diagnostic efficacy of LAP and CVAI for DR. METHODS: A total of 263 participants were recruited in this cross-sectional study. We enrolled 169 patients with T2DM, divided into the non-DR group (NDR, n = 61), non-proliferative DR group (NPDR, n = 55), and proliferative DR group (PDR, n = 53). And we also enrolled 94 healthy control participants. We collected demographic, anthropometric, and biochemical data on each subject. LAP and CVAI are calculated according to different formulas for men and women. RESULTS: Compared with the control group, LAP and CVAI were significantly higher (P < 0.05). After adjusting for confounding factors, LAP (OR: 1.029, 95CI%: 1.010–1.049, P < 0.05), WC (OR: 1.073, 95CI%: 1.009–1.141, P < 0.05) and CVAI (OR: 1.017, 95CI%: 1.000–1.033, P < 0.05) were all associated with an increased risk of DR. Furthermore, increased LAP (OR: 1.020, 95% CI: 0.100–0.290) is associated with DR severity (P < 0.001). Moreover, the LAP had the most significant area under the receiver operating characteristics (ROC) curve (AUC) (AUC = 0.728, 95% CI: 0.653–0.804). CONCLUSION: A high LAP is associated with an increased risk of DR in T2DM patients, and the LAP index appears to be a good predictor of DR risk and severity in patients with T2DM, compared with BMI, WC, and CVAI.
format Online
Article
Text
id pubmed-8721021
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-87210212022-01-06 Association Among Lipid Accumulation Product, Chinese Visceral Obesity Index and Diabetic Retinopathy in Patients with Type 2 Diabetes: A Cross-Sectional Study Li, Xin Li, Hui-Yao Yu, Zi-Wei Zhang, Yi-Tong Tong, Xue-Wei Gao, Xin-Yuan Diabetes Metab Syndr Obes Original Research BACKGROUND AND AIM: Obesity often coexists with diabetes, especially abdominal obesity, recognized as a risk factor for diabetic complications. Diabetic retinopathy (DR), as one of the most common microvascular complications of diabetes, may be associated with these indices. Lipid accumulation product (LAP) and Chinese visceral obesity index (CVAI) are novel visceral obesity indicators, which have been proven to be an influential factor predicting type 2 diabetes (T2DM). However, the correlation among LAP, CVAI, and DR still lacks systematic research in T2DM. The study aimed to explore the relationship among LAP, CVAI levels in different DR stages of T2DM patients and the diagnostic efficacy of LAP and CVAI for DR. METHODS: A total of 263 participants were recruited in this cross-sectional study. We enrolled 169 patients with T2DM, divided into the non-DR group (NDR, n = 61), non-proliferative DR group (NPDR, n = 55), and proliferative DR group (PDR, n = 53). And we also enrolled 94 healthy control participants. We collected demographic, anthropometric, and biochemical data on each subject. LAP and CVAI are calculated according to different formulas for men and women. RESULTS: Compared with the control group, LAP and CVAI were significantly higher (P < 0.05). After adjusting for confounding factors, LAP (OR: 1.029, 95CI%: 1.010–1.049, P < 0.05), WC (OR: 1.073, 95CI%: 1.009–1.141, P < 0.05) and CVAI (OR: 1.017, 95CI%: 1.000–1.033, P < 0.05) were all associated with an increased risk of DR. Furthermore, increased LAP (OR: 1.020, 95% CI: 0.100–0.290) is associated with DR severity (P < 0.001). Moreover, the LAP had the most significant area under the receiver operating characteristics (ROC) curve (AUC) (AUC = 0.728, 95% CI: 0.653–0.804). CONCLUSION: A high LAP is associated with an increased risk of DR in T2DM patients, and the LAP index appears to be a good predictor of DR risk and severity in patients with T2DM, compared with BMI, WC, and CVAI. Dove 2021-12-29 /pmc/articles/PMC8721021/ /pubmed/35002269 http://dx.doi.org/10.2147/DMSO.S348195 Text en © 2021 Li et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Li, Xin
Li, Hui-Yao
Yu, Zi-Wei
Zhang, Yi-Tong
Tong, Xue-Wei
Gao, Xin-Yuan
Association Among Lipid Accumulation Product, Chinese Visceral Obesity Index and Diabetic Retinopathy in Patients with Type 2 Diabetes: A Cross-Sectional Study
title Association Among Lipid Accumulation Product, Chinese Visceral Obesity Index and Diabetic Retinopathy in Patients with Type 2 Diabetes: A Cross-Sectional Study
title_full Association Among Lipid Accumulation Product, Chinese Visceral Obesity Index and Diabetic Retinopathy in Patients with Type 2 Diabetes: A Cross-Sectional Study
title_fullStr Association Among Lipid Accumulation Product, Chinese Visceral Obesity Index and Diabetic Retinopathy in Patients with Type 2 Diabetes: A Cross-Sectional Study
title_full_unstemmed Association Among Lipid Accumulation Product, Chinese Visceral Obesity Index and Diabetic Retinopathy in Patients with Type 2 Diabetes: A Cross-Sectional Study
title_short Association Among Lipid Accumulation Product, Chinese Visceral Obesity Index and Diabetic Retinopathy in Patients with Type 2 Diabetes: A Cross-Sectional Study
title_sort association among lipid accumulation product, chinese visceral obesity index and diabetic retinopathy in patients with type 2 diabetes: a cross-sectional study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721021/
https://www.ncbi.nlm.nih.gov/pubmed/35002269
http://dx.doi.org/10.2147/DMSO.S348195
work_keys_str_mv AT lixin associationamonglipidaccumulationproductchinesevisceralobesityindexanddiabeticretinopathyinpatientswithtype2diabetesacrosssectionalstudy
AT lihuiyao associationamonglipidaccumulationproductchinesevisceralobesityindexanddiabeticretinopathyinpatientswithtype2diabetesacrosssectionalstudy
AT yuziwei associationamonglipidaccumulationproductchinesevisceralobesityindexanddiabeticretinopathyinpatientswithtype2diabetesacrosssectionalstudy
AT zhangyitong associationamonglipidaccumulationproductchinesevisceralobesityindexanddiabeticretinopathyinpatientswithtype2diabetesacrosssectionalstudy
AT tongxuewei associationamonglipidaccumulationproductchinesevisceralobesityindexanddiabeticretinopathyinpatientswithtype2diabetesacrosssectionalstudy
AT gaoxinyuan associationamonglipidaccumulationproductchinesevisceralobesityindexanddiabeticretinopathyinpatientswithtype2diabetesacrosssectionalstudy